Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study)

Trial Profile

Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CAPITAL
  • Most Recent Events

    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
    • 02 Dec 2015 Status changed from not yet recruiting to recruiting, according to University Hospital Medical Information Network - Japan record.
    • 27 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top